BullFrog to Host Webinar on New Precision AI Capability
Rhea-AI Summary
BullFrog AI (NASDAQ: BFRG) will host a webinar on March 27, 2026 at 11 a.m. ET to introduce a new precision AI scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The capability complements bfPREP and bfLEAP by adding a strategic decision‑support layer.
The platform compares drug programs and trial designs without arbitrary scores, tests decisions against multiple scenarios, and produces auditable, assumption‑driven outputs to support governance, cross‑functional alignment, and trial optimization.
Positive
- None.
Negative
- None.
News Market Reaction – BFRGW
On the day this news was published, BFRGW gained 37.24%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI’s new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design
GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI’s new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET.
The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies, revealing which drug target discovery or clinical trial strategies are robust winners and which succeed only under narrow conditions.
Key capabilities of the new BullFrog AI platform include comparing drug programs, indications, and trial designs without forcing arbitrary numerical scores, as well as testing portfolio decisions against multiple specific scenarios and more. Please visit the BullFrog AI website for updates on the new product launch.
Webinar Speaker
The webinar will be led by Juan Felipe Beltrán Lacouture, PhD, BullFrog AI Senior Director of AI, Machine Learning & Innovation.
Webinar Overview
Hosted in partnership with Xtalks Life Sciences, the webinar will present BullFrog AI’s latest product, a novel structured decision-support tool that replaces arbitrary scoring with transparent, repeatable comparisons. The tool organizes available evidence, supports consistent evaluation across alternatives and generates outputs with a clear and auditable rationale. Rather than compressing uncertainty into a single composite score, the tool explicitly describes underlying assumptions and evidence drivers, enabling stakeholders to understand what influences a ranking and what conditions could alter an outcome.
Attendees will learn how structured decision environments can support cross-functional alignment, improve confidence in portfolio and trial strategy decisions and strengthen governance without requiring extensive system changes. Practical use cases will be discussed, including portfolio prioritization, target selection, biomarker strategy and clinical trial optimization.
Registration for this webinar can be found here.
About BullFrog AI
BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com.
About Xtalks Life Sciences
Xtalks Life Sciences brings together professionals across pharma, biotech, medtech, healthcare and research through trusted knowledge, meaningful connections and collaborative innovation. Focused on the highly regulated life sciences sector, the company delivers a dynamic portfolio of expert content, including webinars, news, blogs, podcasts, videos, virtual events and thought-provoking editorial offerings. These resources are designed to support informed decision-making and accelerate progress.
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Investors:
CORE IR
ir@bullfrogai.com
Media:
CORE PR
pr@bullfrogai.com
FAQ
When is BullFrog AI (BFRG) hosting the webinar on the new precision AI capability?
What does BullFrog AI's new decision engine for BFRG do?
Who will present BullFrog AI's (BFRG) webinar on March 27, 2026?
How will the new BullFrog AI tool affect clinical trial design decisions for BFRG stakeholders?
Does BullFrog AI's new platform integrate with existing products like bfPREP and bfLEAP for BFRG?
What practical use cases will BullFrog AI (BFRG) cover in the webinar?
